For ARO-SNCA, Arrowhead Pharmaceuticals’ preclinical-stage siRNA therapy that targets alpha-synuclein for the treatment of synucleinopathies, and for other collaboration targets using Arrowhead’s exclusive Targeted RNAi Molecule (TRiM™) platform, Gibson Dunn is providing advice to the company on its global licensing and collaboration agreement with Novartis.